Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational status and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until June 3, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint alleges that Viatris misrepresented its facilities as being in "good operating condition" and committed to high-quality manufacturing standards, despite a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has significantly impacted Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results, Viatris disclosed that the negative impact from the Indore facility's inspection would reduce 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price fell roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the June 3, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Viatris securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must move the Court by June 3, 2025 [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that would prevent shipping eleven products [4] - Defendants allegedly downplayed the impact of the FDA warning letter, referring to it as a "minor headwind," while failing to disclose critical details about the inspection and remediation efforts [5] - The misleading statements led investors to purchase Viatris securities at artificially inflated prices, resulting in damages when the true information became public [5]

PHILADELPHIA, May 23, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired VIATRIS securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff represent ...

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented the condition of its facilities, stating they were in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - Following the disclosure of the inspection's ramifications, Viatris projected a revenue decrease of approximately $500 million and an earnings reduction of about $385 million for 2025 [5]. - On February 27, 2025, Viatris's stock price fell roughly 15%, from $11.24 per share to $9.53 per share, in response to the negative news [5].

Core Viewpoint - A class action securities lawsuit has been filed against Viatris Inc. due to alleged securities fraud impacting investors between August 8, 2024, and February 26, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Viatris misrepresented the implications of a warning letter from the FDA regarding its Indore, India facility, downplaying its significance as a "minor headwind" [2] - Following the announcement of disappointing financial results for Q4 and full fiscal year 2024 on February 27, 2025, Viatris' stock price dropped from $11.24 to $9.53 per share, a decline of approximately 15.21% in one day [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

PITTSBURGH, May 22, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in June 2025.The Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 8:10 a.m. ET.In addition, the Company will take part in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9, 2025, at 10:40 a.m. ET.Investors and the genera ...

NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=149527&from=4CLASS PERIOD: August 8, 2024 to February ...

Core Viewpoint - A securities class action lawsuit has been filed against Viatris Inc. for allegedly misleading investors during the Class Period from August 8, 2024, to February 26, 2025 [1][3]. Company Overview - Viatris is a healthcare company based in Canonsburg, PA, that provides medicines to one billion patients globally [2]. Legal Context - The lawsuit claims that Viatris misled investors by downplaying the consequences of a failed inspection at its Indore, India facility and a Warning Letter from the U.S. Food and Drug Administration [3]. - Investors who purchased Viatris securities during the Class Period have until June 3, 2025, to seek appointment as lead plaintiff [2]. Law Firm Background - Berger Montague, the law firm handling the case, has been involved in securities class action litigation since 1970 and has represented both individual and institutional investors [5].

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, captioned Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company supplying medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented its facilities as being in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter issued by the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - On February 27, 2025, Viatris disclosed that the failed inspection would lower 2025 revenue by approximately $500 million and earnings from operations by approximately $385 million, leading to a stock price decline of about 15% in one trading day [5].

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission- ...